SEARCH

SEARCH BY CITATION

References

  • 1
    Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336:347356.
  • 2
    Sim KH, Wojcik JP, Margulies M, Wade J, Heathcote J. Human leukocyte antigen class II alleles may affect response of chronic hepatitis C to Interferon therapy. J Viral Hepat 1998; 5:249253.
  • 3
    Piazzolla G, Tortorella C, Fiore G, Fanelli M, Pisconti A, Antonaci S. Interleukin-12 p40/p70 ratio and in vivo responsiveness to IFN-alpha treatment in chronic hepatitis C. J Interferon Cytokine Res 2001; 21:453461.
  • 4
    Gomez-Rubio M, Porres JC, Castillo I, Quiroga JA, Moreno A, Carreno V. Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group. J Hepatol 1990; 11:S63S67.
  • 5
    Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C with high-dose interferon alpha 2b. A multicenter study. Dig Dis Sci 1993; 38:612618.
  • 6
    Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology 1997; 26(Suppl 1):122S.
  • 7
    Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22:10501056.
  • 8
    Reddy KR, Hoofnagle JH, Tong MJ. Racial differences in response to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30:78.
  • 9
    Perez R, Pravia R, Linares A, Rodriguez M, Lombrana JL, Suarez A, Riestra S, et al. Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C. Gut 1993; 34(Suppl):S139S140.
  • 10
    Camps J, Crisostomo S, Garcia-Granero M, Riezu-Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut 1993; 34:17141717.
  • 11
    Hayashi J, Kishihara Y, Ueno K, Yamaji K, Kawakami Y, Furusyo N, Sawayama Y, et al. Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Arch Intern Med 1998; 158:177181.
  • 12
    Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29:12151219.
  • 13
    Clouston AD, Jonsson JR, Purdie DM, Macdonald GA, Pandeya N, Shorthouse C, Powell EE. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001; 34:314320.
  • 14
    Giannini E, Ceppa P, Botta F, Mastracci L, Romagnoli P, Comino I, Pasini A, et al. Leptin has no role in determining severity of steatosis and fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2000; 95:32113217.
    Direct Link:
  • 15
    Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:13581364.
  • 16
    Poynard T. Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:14261432.
  • 17
    Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:16661672.
  • 18
    Lam NP, DeGuzman LJ, Pitrak D, Layden TJ. Clinical and histologic predictors of response to interferon-α in patients with chronic hepatitis C viral infection. Dig Dis Sci 1994; 39:26602664.
  • 19
    Lam NP, Pitrak D, Speralakis R, Lau AH, Wiley TE, Layden TJ. Effect of obesity on pharmacokinetics and biologic effect of interferon-α in hepatitis C. Dig Dis Sci 1997; 42:178185.
  • 20
    Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:24672474.
    Direct Link:
  • 21
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22:696699.
  • 22
    Kutami R, Girgrah N, Wanless IR, Sniderman K, Wong FS, Sherman M, Heathcote J, et al. The Laennec grading system for assessment of hepatic fibrosis: validation by correlation with edged hepatic vein pressure and clinical features [Abstract]. Hepatology 2000; 32:407a.
  • 23
    The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology 1994; 20:1520.
  • 24
    Wellens RI, Roche AF, Khamis HJ, Jackson AS, Pollock ML, Siervogel RM. Relationships between the body mass index and body composition. Obes Res 1996; 4:3544.
  • 25
    Giannini E, Ceppa P, Botta F, Fasoli A, Romagnoli P, Cresta E, Venturino V, et al. Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients. Liver 1999; 19:432437.
  • 26
    Giannini E, Ceppa P, Testa R. Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy? J Hepatol 2001; 35:432433.
  • 27
    Rubbia-Brandt L, Giostra E, Mentha G, Quadri R, Negro F. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol 2001; 35:307.
  • 28
    Porter CJH, Charman SA. Lymphatic transport of proteins after subcutaneous administration (mini-review). J Pharm Sci 2000; 89:297310.
  • 29
    Banerjee D, Williams EV, Ilott J, Monypenny IJ, Webster DJ. Obesity predisposes to increased drainage following axillary node clearance: a prospective audit. Ann R Coll Surg Engl 2001; 83:268271.